Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
Education Center - SponsoredBringing specialist level interpretation in-clinicby • Zoetis DiagnosticsImagine a busy weekday morning in a typical small animal clinic. The appointments are fully booked, the phones are ringing, and in comes Yogi, a five year old terrier mix whose owners are clearly worried.
